1st Capital Partner leads series-A extension for Hemovent

The original funding round closed on $6m in February 2016, at which stage the company had filed a patent application for its device.

All backers of the original round have reinvested, including MIG Verwaltungs, WCTI Partners, Seed Fond Aachen II, KfW Bank, NRW Bank Venture Fond and PB Beteiligung- und Vermoegensverwaltung.

Hemovent completed in-vivo trials last month and aims to use the funding to make its technology available by mid-2018.

Company
Based in Aachen and founded in 2013, Hemovent is a medical device company developing a small and portable extra-corporeal membrane oxygenation system that supports or replaces heart and lung function in the event of cardiac and respiratory failure. The Hemovent system is not yet approved for human use.

People
Hemovent – Christof Lenz (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture